Press Releases

November 18, 2014

BioCrea’s Anti Depression Program Voted “Top Neuroscience Project to Watch”

Radebeul, Germany, November 18, 2014 – BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that the Company’s NMDA NR2B NAM program has been chosen as one of the “Top Neuroscience Projects to Watch” by Informa’s IN VIVO, Start-up and The Pink Sheet. The NMDA NR2B small molecule program is currently being developed to treat Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD).

BioCrea has been invited to present the project at the Therapeutic Area Partnerships (TAP) meeting, which takes place on November 19-21, 2014 in Boston, USA:

Session: Track 1: Neuroscience
Presentation: Dr. Tom Kronbach, CEO of BioCrea
Title: “On Target with Rapid Acting Antidepressants”
Date and Time: Thursday, November 20, 2014, 11:40 AM EST
Location: The Hyatt Regency Boston, Room: Duxbury

“Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider to be the most attractive opportunities the industry has to offer,” said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. “As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners and acquirers.”

The “Top Neuroscience Projects to Watch” have been chosen by independent industry experts. BioCrea met the selection criteria, which included: an unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.

“We are complimented to be selected as one of the ‘Top Neuroscience Projects to Watch’ by these independent Informa experts”, said Dr. Tom Kronbach, CEO of BioCrea GmbH. “We very much appreciate this opportunity to discuss our NMDA NR2B NAM program at the TAP meeting, which is one of the key neuroscience events.”

About BioCrea

BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychiatric disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). For more information, please visit

About the Therapeutic Area Partnerships (TAP)

A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas).

Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events.


Dr. Tom Kronbach
CEO, BioCrea GmbH

Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216



BioCrea’s Anti Depression Program Voted “Top Neuroscience Project to Watch” (english | pdf)

BioCreas Anti-Depressiva-Programm zum „Top Neuroscience Project to Watch“ gewählt (deutsch | pdf)